Navigation Links
JCI table of contents: Aug. 16, 2007
Date:8/16/2007

formation in the eye led the authors to suggest that inhibiting S1P2R activation in the retina might provide a new therapeutic approach to treating diseases of the eye caused by the presence of an abnormal blood vessel network.

TITLE: Essential role of sphingosine 1–phosphate receptor 2 in pathological angiogenesis of the mouse retina

AUTHOR CONTACT: Timothy Hla University of Connecticut School of Medicine, Farmington, Connecticut, USA. Phone: (860) 679-4128; Fax: (860) 679-1201; E-mail: hla@nso2.uchc.edu.

Christopher DeFrancesco Office of Communications University of Connecticut Health Center, Farmington, Connecticut, USA. Phone: 860-679-3914; E-mail: cdefrancesco@uchc.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=31123


ONCOLOGY: A winning combination for the treatment of cancer

The immune system does not destroy tumors even though they express molecules that should activate immune cells. The immune system is therefore said to be tolerant of the tumors. Several molecules and cell types have been implicated in the induction of immune system tolerance to tumors, including, in mice, a small population of immune cells known as plasmacytoid dendritic cells (pDCs) that produce the enzyme indoleamine 2,3-dioxygenase (IDO) and that are isolated from the lymph nodes that drain the site of the tumor. Now, researchers from the Medical College of Georgia, Augusta, have identified how these mouse IDO-expressing pDCs induce tumor-specific immune tolerance.

In the study, which appears online on August 16 in advance of publication in the September print issue of the Journal of Clinical Investigation, David Munn and colleagues found that mouse IDO-expressing pDCs from tumor-draining lymph nodes directly activate the suppressive f
'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related biology news :

1. Highly adaptable genome in gut bacterium key to intestinal health
2. Development of portable infectious disease detector
3. Scientists identify genes responsible for black rot disease in vegetables
4. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
5. Aloe vera coating may prolong freshness, safety of fruits and vegetables
6. Nanotechnology to provide portable genetic risk detection
7. New study shows patients more willing to consider self-injectable HIV therapy than many physicians anticipate
8. Implantable pumps extend lives of patients too sick for transplant
9. Bioengineers create stable networks of blood vessels
10. Portable cocaine sensor developed at UC Santa Barbara
11. Researchers develop portable vein finder for faster, more accurate injections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
(Date:8/5/2015)... , August 5, 2015 ... titled "Facial Recognition Market - Global Industry Analysis, Size, ... global market for facial recognition is forecast to reach ... by increased demand for surveillance systems by civil and ... number of crimes and terrorist activities across the globe ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... difficult to eliminate tumours effectively. Deciphering the strategies ... tumour cells and thus improve the clinical perspectives for ... and CNRS researchers have used two-photon microscopy to demonstrate, ... T lymphocytes infiltrate a solid tumour in order to ...
... discovered that the same ingredient used in dandruff shampoos ... head also can calm overexcited nerve cells inside your ... of the study can be found online in Nature ... result when nerves excessively or inappropriately “fire?in the brain. ...
... have developed two strategies to reactivate the p53 gene in ... The p53 protein is called the "guardian of the genome" ... , Inactivation of p53 can set the stage for the ... for the first time that inactivating the p53 gene is ...
Cached Biology News:How T lymphocytes attack 2How T lymphocytes attack 3Anti-dandruff compound may help fight epilepsy 2Turning a cellular sentinel into a cancer killer 2Turning a cellular sentinel into a cancer killer 3Turning a cellular sentinel into a cancer killer 4
(Date:8/31/2015)... ... August 31, 2015 , ... ... priority in the drug development approval process. Thus, innovator companies must understand what ... Technologies, Inc., a Chicago-based CMO, has been hosting multiple educational panels and seminars ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive ... commercially available new FDA approved system in the last 14 years, and the only ... Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and ...
(Date:8/30/2015)... England , August 31, 2015 /PRNewswire/ ... 51-jährige Wartezeit   einer Frau   für chirurgische   ... Alter von 7-90   werden für eine ... Programm soll 1200 Frauen behandeln und die Anzahl ausgebildeter ... Astellas gab heute bekannt, dass  Action ...
(Date:8/28/2015)... 2015 According to a new ... Storage Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, ... End User - Global Forecast to 2020", published by ... USD 3,731.03 Million by 2020 from USD 2,150.48 Million ... 2015 and 2020. Browse 74 Tables ...
Breaking Biology Technology:Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5
... available in German . , They have been ... and now they are making rapid inroads in high performance ... cell phones and digital cameras. The automotive industry, for instance, ... increasingly using them in driver assistance systems from parking ...
... Scarguard Labs, LLC, a closely held company specializing in ... through the use of multi-technology drugs enhanced by a ... received approval from Health Canada to sell Scarguard to ... very pleased to gain approval for retail in our ...
... NEW YORK, Feb. 23, 2011 Stemline Therapeutics, Inc., ... that target cancer stem cells (CSCs), today announced that ... ("Pitt"), for the exclusive worldwide rights to a clinically ... tumor bulk and CSCs. Developed by Dr. Hideho Okada, ...
Cached Biology Technology:UV-transparent coating for image sensors 2Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh 2Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh 3
...
... Normal;heading 1;heading 2;Many ... and experimental situations ... standard transfection and ... systems. ViraPower Lentiviral ...
LTBP-2 (7B10)...
... Rabbit polyclonal to Kv4.2 Immunogen ... corresponding to amino acids 23-43 of Rat ... with Rat.Expected to cross-react with Human (100% ... immunogen), Rabbit (100% identity with immunogen) and ...
Biology Products: